Attenda nce at this event is complimentary.
\n \nTh e event is primarily aimed at innovators\, biotech s\, and policymakers across the life sciences ecos ystem with an interest in exploring practical appl ications\, as well as the legal and ethical consid erations and strategies for responsible AI adoptio n.
\n \nAll registrations are subject to re view to ensure they align with the intended audien ce for the event. Where a registration does not me et these criteria\, it may not be accepted. You wi ll be informed if your registration has been cance lled within 2 working days of registering online f or the event.
\n \nFrom accelerating drug d iscovery and enabling precision medicine to improv ing diagnostics\, clinical trials\, and healthcare operations\, AI is reshaping the future of life s ciences. But with new technology comes new risk. A longside questions of adoption and implementation\ , organisations must also consider key legal and g overnance issues\, including contracts\, intellect ual property\, and data protection when using AI t ools. How can life science companies unlock AI’s p otential while effectively mitigating uncertainty and risk?
\n \nThe format will include a pa nel discussion and audience segment where you can help shape the agenda by sharing the AI challenges and opportunities that matter most to you.
\n \nAgenda:
\n 08:30 – 09:
00 Arrival\, Networking and Refreshments
\n 0
9:00 – 10:15 Panel Insights and Interactive Discus
sion
\n Moderator: Aline Charpentier\, Scienc
e Strategy and Innovation Lead\, Wellcome Genome C
ampus
\n Panellists: Sunil Jindal\, Regional
Director\, Freeman Clarke\; Matthew Clark\, Cyber
Director\, Partners&\; Rachel Bradley\, Partner –
IP/IT/Commercial\, Penningtons Manches Cooper
\n 10:15 – 11:00 Networking Continues and Close
DESCRIPTION:Attendance at this event is complimentary.\n \n \n
\n The event is primarily aimed at innovators\, b
iotechs\, and policymakers across the life science
s ecosystem with an interest in exploring practica
l applications\, as well as the legal and ethical
considerations and strategies for responsible AI a
doption.\n \n \n \n All registrations are subject
to review to ensure they align with the intended a
udience for the event. Where a registration does n
ot meet these criteria\, it may not be accepted. Y
ou will be informed if your registration has been
cancelled within 2 working days of registering onl
ine for the event.\n \n \n \n From accelerating dr
ug discovery and enabling precision medicine to im
proving diagnostics\, clinical trials\, and health
care operations\, AI is reshaping the future of li
fe sciences. But with new technology comes new ris
k. Alongside questions of adoption and implementat
ion\, organisations must also consider key legal a
nd governance issues\, including contracts\, intel
lectual property\, and data protection when using
AI tools. How can life science companies unlock AI
’s potential while effectively mitigating uncertai
nty and risk?\n \n \n \n The format will include a
panel discussion and audience segment where you c
an help shape the agenda by sharing the AI challen
ges and opportunities that matter most to you.\n \
n \n \n Agenda:\n \n 08:30 – 09:00 Arrival\, Netwo
rking and Refreshments\n \n 09:00 – 10:15 Panel In
sights and Interactive Discussion\n \n Moderator:
Aline Charpentier\, Science Strategy and Innovatio
n Lead\, Wellcome Genome Campus\n \n Panellists: S
unil Jindal\, Regional Director\, Freeman Clarke\;
Matthew Clark\, Cyber Director\, Partners&\; Rach
el Bradley\, Partner – IP/IT/Commercial\, Penningt
ons Manches Cooper\n \n 10:15 – 11:00 Networking C
ontinues and Close\n \n
CATEGORIES:Events
CALSCALE:GREGORIAN
DTSTAMP;TZID=Europe/London:20260602T083000
DTSTART;TZID=Europe/London:20260602T083000
DTEND;TZID=Europe/London:20260602T110000
LOCATION:BioData Innovation Centre (BIC)\n Wellcome Genome
Campus\n Hinxton\n Cambridge\, CB10 1SA\n United K
ingdom\n
URL:https://onenucleus.com/civicrm/event/info?reset=1&id=1981
END:VEVENT
END:VCALENDAR